Anhui Fengyuan Pharmaceutical Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	8.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.3yrs

Jüngste Management Updates

Recent updates

Anhui Fengyuan Pharmaceutical's (SZSE:000153) Anemic Earnings Might Be Worse Than You Think

May 07

Anhui Fengyuan Pharmaceutical Co., Ltd.'s (SZSE:000153) Business And Shares Still Trailing The Market

Apr 17

Geschäftsführer

Anhui Fengyuan Pharmaceutical hat keinen Geschäftsführer, oder es liegen keine verfügbaren Daten vor.

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jun Li	Financial Director	7.5yrs	CN¥398.00k	0.12% CN¥ 3.1m
Shaoyi Zhang	Deputy GM & Director	17.4yrs	CN¥576.00k	0.090% CN¥ 2.4m
Zhenhong Lu	Deputy GM & Director	4yrs	CN¥462.00k	0.11% CN¥ 2.8m
Tianle Ru	GM & Director	8.7yrs	CN¥684.00k	0.30% CN¥ 7.9m
Jinchao Duan	Deputy GM & Director	5.3yrs	CN¥324.00k	0.060% CN¥ 1.6m
Jun Zhang	Secretary of the Board & Non-Independent Director	25.9yrs	CN¥330.00k	0.14% CN¥ 3.6m
Guo Kun Li	Deputy General Manager	11.4yrs	CN¥386.00k	0.060% CN¥ 1.6m
Shuang Qing Yin	Deputy General Manager	5.3yrs	CN¥368.00k	0.090% CN¥ 2.4m

8.1yrs

Durchschnittliche Betriebszugehörigkeit

50.5yo

Durchschnittliches Alter

Erfahrenes Management: 000153Das Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (7.8 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Shaoyi Zhang	Deputy GM & Director	9.9yrs	CN¥576.00k	0.090% CN¥ 2.4m
Zhenhong Lu	Deputy GM & Director	8.5yrs	CN¥462.00k	0.11% CN¥ 2.8m
Tianle Ru	GM & Director	2.2yrs	CN¥684.00k	0.30% CN¥ 7.9m
Jinchao Duan	Deputy GM & Director	2.2yrs	CN¥324.00k	0.060% CN¥ 1.6m
Jun Zhang	Secretary of the Board & Non-Independent Director	4.3yrs	CN¥330.00k	0.14% CN¥ 3.6m
Hongman He	Chairman of the Board	16.5yrs	CN¥760.00k	0.45% CN¥ 11.9m
Yue'e Hu	Chairman of Supervisory Board	2.2yrs	CN¥420.00k	keine Daten
Weidong Zhu	Independent Director	5.3yrs	CN¥60.00k	keine Daten
Jiemiao Chen	Independent Director	5.3yrs	CN¥60.00k	keine Daten
Jinsheng Hu	Non-Employee Supervisor	5.3yrs	keine Daten	keine Daten
Cisheng Wu	Independent Director	2.2yrs	CN¥30.00k	keine Daten
Hui Yan Sun	Supervisor	5.3yrs	keine Daten	keine Daten

5.3yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrener Vorstand: 000153Die Vorstandsmitglieder gelten als erfahren (4.9 Jahre durchschnittliche Amtszeit).

Anhui Fengyuan Pharmaceutical Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Anhui Fengyuan Pharmaceutical Co., Ltd., Annual General Meeting, May 22, 2024

Less than half of directors are independent

High number of new directors

Anhui Fengyuan Pharmaceutical Co., Ltd. Announces Management Appointments

High number of new and inexperienced directors

Recent updates

Now 22% overvalued after recent price rise

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.12 in 2Q 2023)

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Dividend increased to CN¥0.15

Anhui Fengyuan Pharmaceutical Co., Ltd. Announces 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 07 June 2024

Anhui Fengyuan Pharmaceutical's (SZSE:000153) Anemic Earnings Might Be Worse Than You Think

Anhui Fengyuan Pharmaceutical Co., Ltd., Annual General Meeting, May 22, 2024

Anhui Fengyuan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend (Tax Included) for 2023

First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.14 in 1Q 2023)

Now 23% overvalued

Anhui Fengyuan Pharmaceutical Co., Ltd.'s (SZSE:000153) Business And Shares Still Trailing The Market

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment deteriorates as stock falls 18%

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.12 in 3Q 2022)

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.17 in 2Q 2022)

Anhui Fengyuan Pharmaceutical Announces Cash Dividend for 2022

Full year 2022 earnings released: EPS: CN¥0.49 (vs CN¥0.37 in FY 2021)

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.085 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.12 in 2Q 2021)

Anhui Fengyuan Pharmaceutical Co., Ltd. Announces Management Appointments

Anhui Fengyuan Pharmaceutical Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 05 July 2022

Anhui Fengyuan Pharmaceutical Co., Ltd. Approves Cash Distribution for 2021

Anhui Fengyuan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Third quarter 2021 earnings released: EPS CN¥0.085 (vs CN¥0.041 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.12 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.26 in FY 2019)

Investor sentiment improved over the past week

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 23, 2021

New 90-day low: CN¥6.62

Investor sentiment deteriorated over the past week

New 90-day low: CN¥7.79

New 90-day low: CN¥8.07

New 90-day low: CN¥8.22

Third quarter earnings released

First half earnings released

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥12.49

Geschäftsführer

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter